Overexpression of OATP1B3 in prostate cancer may be beneficial to chemotherapy but can be detrimental to hormone therapy because OATP1B3 drives testosterone uptake in cancer cells, leading to the development of resistance to androgen deprivation therapy (ADT).113. This evidence concerns the gene SLCO1B3 and prostate carcinoma.